JUPITER, FL May. 5, 2017 — Somahlution, a global biotechnology company developing products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical...
Read moreNews
27 Jun, 2017
27 Jun, 2017
Somahlution Announces DuraGraft Registry Initiation at Leading Cardiac Surgery Hospitals in Germany
27 Jun, 2017
JUPITER, Fl.- Somahlution announces the first German patient enrolled in its DuraGraft® European Registry clinical trial. The patient was treated by Dr. Prof. Herbert Vetter, Chief Physician at Helios Hospital Wuppertal....
Read more07 Apr, 2017
Somahlution Announces Study Results Showing DuraGraft® Vascular Graft Treatment Improves Long-Term Outcomes in Coronary Artery Bypass Grafting Surgery
07 Apr, 2017
Somahlution Announces Study Results Showing DuraGraft® Vascular Graft Treatment Improves Long-Term Outcomes in Coronary Artery Bypass Grafting Surgery First-in-class intraoperative vascular graft treatment shown to reduce the risk of...
Read more28 Feb, 2017
Somahlution announced enrollment of the first subject in their DuraGraft® CABG European Registry
28 Feb, 2017
JUPITER, Fla., Jan. 4, 2017 — Somahlution, a global biotechnology company developing products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications,...
Read more28 Feb, 2017
Somahlution Announces Multiple Site Initiation and Patient Enrollment in Spain for European DuraGraft ®Registry.
28 Feb, 2017
Somahlution Announces Multiple Site Initiation and Patient Enrollment in Spain for European DuraGraft Registry.
Read more